ABC | Volume 112, Nº5, Maio 2019

Diretriz Diretriz Brasileira de Cardiologia Fetal – 2019 Arq Bras Cardiol. 2019; 112(5):600-648 109. Hooper CW, Delaney C, Streeter T, Yarboro MT, Poole SD, Brown N, et al. Selective serotonin reuptake inhibitor (SSRI) exposure constricts the mouse ductus arteriosus in utero. Am J Physiol Heart Circ Physiol. 2016;311(3):H572-81. 110. WeintraubA, MankutaD. Dipyrone-induced oligohydramnios and ductus arteriosus restriction. Isr Med Assoc J. 2006;8(10):722-3. 111. Delaney C, Gien J, Roe G, Isenberg N, Kailey J, Abman SH. Serotonin contributes to high pulmonary vascular tone in a sheepmodel of persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol. 2013;304(12):L894-901. 112. Momma K, Nishihara S, Ota Y. Constriction of the fetal ductus arteriosus by glucocorticoid hormones. Pediatr Res. 1981;15(1):19-21. 113. Hassid A. Regulation of prostaglandin biosynthesis in cultured cells. Am J Physiol. 1982;243(5):C205-11. 114. Wasserstrum N, Huhta JC, Mari G, Sharif DS, Willis R, Neal NK. Betamethasone and the human fetal ductus arteriosus. Obstet Gynecol. 1989;74(6):897-900. 115. Faller AL, Fialho E. Polyphenol content and antioxidant capacity in organic and conventional plant foods. J Food Comp Anal. 2010;23(6):561-68. 116. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probablemechanisms of action and potential applications. Am J Clin Nutr. 2001;74(4):418-25. 117. Wollgast J, Anklam E. Polyphenols in chocolate: Is there a contribution to human health? Food Res Int. 2000;33(6):449-59. 118. Rios-Hoyo A, Cortes MJ, Rios-Ontiveros H, Meaney E, Ceballos G, Gutierrez-Salmean G. Obesity, metabolic syndrome, and dietary therapeutical approaches with a special focus on nutraceuticals (Polyphenols): amini-review. Int J VitamNutr Res. 2014;84(3-4):113-23. 119. Efraim P, Alves AB, Jardim DC. Review: Polyphenols in cocoa and derivatives: factors of variation and health effects. Braz J Food Technol. 2011;14(3):181-201. 120. Halliwell B. How to characterize a biological antioxidant. Free Radic Res Commun. 1990;9(1):1-32. 121. Zielinsky PM, Manica JL, Piccoli Jr A, Areias JC, Nicoloso LH, Menezes HS, et al. Experimental study of the role of maternal consumption of green tea, mate tea and grape juice on fetal ductal constriction. 17th World Congress onUltrasound inObstetrics andGynecology, 2007 - Ultrasound in Obstetrics and Gynecology. 2007;30(4):515. 122. Bubols GB, Zielinsky P, Piccoli AL Jr, Nicoloso LH, Vian I, Moro AM, et al. Nitric oxide and reactive species are modulated in the polyphenol- induced ductus arteriosus constriction in pregnant sheep. Prenat Diagn. 2014;34(13):1268-76. 123. Zielinsky P, Martignoni FV, Vian I. Deleterious effects of maternal ingestion of cocoa upon fetal ductus arteriosus in late pregnancy. Front Pharmacol. 2014;5:281. 124. Zílio AM, Zielinsky P, Vian I, Schaun MI, Markoski M, Lampert K, et al. Polyphenol supplementation inhibits physiological increase of prostaglandin E2 during reproductive period - a randomized clinical trial. Prostaglandins Leukot Essent Fatty Acids. 2017 Apr 5. [Epub ahead of print]. 125. Vian I, Zielinsky P, Zilio AM, SchaunM, BrumC, Lampert KV, et al. Increase of ProstaglandinE2 intheReversalofDuctalConstrictionAfterPolyphenol Restriction. Ultrasound Obstet Gynecol. 2018 Nov;52(5):617-622. 126. Khan HY, Zubair H, Ullah MF, Ahmad A, Hadi SM. A prooxidant mechanism for the anticancer and chemopreventive properties of plant polyphenols. Curr Drug Targets. 2012;13(14):1738-49. 127. Arnt A. Quantificação do conteúdo de polifenóis totais em alimentos consumidos no sul do Brasil. 2015. Dissertação de mestrado. Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, 2015. 128. KleinmanCS,NehgmeRA.Cardiacarrhythmias inthehuman fetus.Pediatr Cardiol. 2004;25(3):234-51. 129. Zielinsky P. [Fetal heart rhythm disorders. Detection and prenatal management]. Arq Bras Cardiol. 1996;66(2):83-6. 130. KleinmanCS, Donnerstein RL, Jaffe CC, DeVoreGR,Weinstein EM, Lynch DC, et al. Fetal echocardiography: a tool for evaluation of in utero cardiac arrhythmias and monitoring of in utero therapy: analysis of 71 patients. Am J Cardiol 1983;51(2):237-43. 131. Zielinsky P, Dillenburg RF, de Lima GG, Zimmer LP. [Fetal supraventricular tachyarrhythmias. Experience of a fetal cardiology referral center]. ArqBras Cardiol 1998;70(5):337-40. 132. Fouron JC, Proulx F, Miro J, Gosselin J. Doppler and M-mode ultrasonography to time fetal atrial and ventricular contractions. Obstet Gynecol. 2000;96(5 Pt 1):732-6. 133. Fouron JC, Fournier A, Proulx F, Lamarche J, Bigras JL, Boutin C, et al. Management of fetal tachyarrhytmia based on superior vena cava/aorta Doppler flow recordings. Heart. 2003;89(10):1211-6. 134. Hornberger LK. Echocardiographic assessment of fetal arrhythmias. Heart. 2007;93(11):1331-3. 135. Carvalho JS, Prefumo F, Ciardelli V, Sairam S, Bhide A, Shinebourne EA. Evaluation of fetal arrhythmias from simultaneous puldes wave Doppler in pulmonary artery and vein. Heart. 2007;93(11):1448-53. 136. Dancea A, Fouron JC, Miró J, Skoll A, Lessard M. Correlation between electrocardiographic and ultrassonographic time-interval measurements in fetal lamb heart. Pediatr Res. 2000;47(3):324-8. 137. Wacker-Gussmann A, Strasburger JF, Cuneo BF, Wakai RT. Diagnosis and treatment of fetal arrhythmia: Am J Peronatol. 2014;31(7):617-28. 138. Strasburger JF, Wakai, RT. Fetal cardiac arrhythmia detection and in utero therapy: Nat Rev Cardiol. 2010;7(5):277-90. 139. Copel JA, Liang RI, Demasio K, Ozeren S, Kleinman CS. The clinical significance of the irregular fetal heart rhythm. Am J Obstet Gynecol. 2000;182(4):813-7. 140. Fouron JC. Fetal arrhythmias: the Saint-justine hospital experience. Prenat Diagn. 2004;24(13):1068-80. 141. Srinivasan S, Strasburger J. Overview of fetal arrhythmias. Curr Opin Pediatr. 2008;20(5):522-31. 142. Eliasson H, Wahren-Herlenius M, Sonesson SE. Mechanisms in fetal bradyarrhythmia: 65 cases in a single center analyzed by Doppler flow echocardiographic techniques. Ultrasound Obstet Gynecol. 2011;37(2):172-8. 143. Breur JM, Oudijk MA, Stoutenbeek P, Visser GH, Meijboom EJ. Transient non-autoimmune fetal heart block. Fetal Diagn Ther. 2005;20(2):81-5. 144. Machado MV, Tynan MJ, Curry PV, Allan LD. Fetal complete heart block. Br Heart J. 1988;60(6):512-5. 145. Schmidt KG, Ulmer HE, Silverman NH, Kleinmann CS, Copel JA. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol. 1991;17(6):1360-6. 146. Cuneo BF, Zhao H, Strasburger JF, Ovadia M, Huhta JC, Wakai RT. Atrial and ventricular rate response and patterns of heart rate acceleration during maternal-fetal terbutaline treatment of fetal complete heart block. Am J Cardiol. 2007;100(4):661-5. 147. SonessonSE,SalomonssonS, JacobssonLA,BremmeK,Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum. 2004;50(4):1253-61. 148. Rein AJ, Mevorach D, Perles Z, Gavri S, Nadjari M, Nir A, et al. Early Diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation. 2009;119(14):1867-72. 149. Aoki H, Inamura N, Kawazu Y, Nakayama M, Kayatani F. Fetal echocardiographic assessment of endocardial fibroelastosis in maternal anti-SSA antibody-associated complete heart block. Circ J. 2011;75(5):1215-21. 150. Krishnan A, Pike JI, Donofrio MT. Prenatal evaluation and management of fetuses exposed to anti SSA/Ro antibodies. Pediatr Cardiol. 2012;33(8):1245-52. 646